![]() |
| HKSTP concluded its first-ever delegation of 22 park companies and local university partners to MEDICA 2026 from 16 to 19 November in Düsseldorf, Germany. |
Running from
November 16 to 19, the showcase featured 22 park companies and local university
partners—working alongside the Hong Kong Trade Development Council (HKTDC) and
the Hong Kong MedTech Association—to spotlight breakthroughs in surgical
robotics, diagnostics, ophthalmology, and rehabilitation.
The
debut marks a strategic push to position Hong Kong as a premier two-way
launchpad: helping Chinese innovators navigate European regulatory landscapes
while offering European firms seamless entry into the Greater Bay Area and
China’s rapidly expanding medical device market, projected to reach USD 82
billion by 2032.
"Turning
breakthroughs into global healthcare solutions requires deep ecosystem
collaboration," said Terry Wong, CEO of HKSTP. "Engaging key European
partners is vital to building trusted cross-border pathways for regulatory
readiness and market access, demonstrating how HKSTP connects world-class
R&D with international markets."
Strategic Alliances and Commercial Deals
To
formalize European market entry, HKSTP inked two landmark Memoranda of
Understanding (MoUs) with German healthtech leaders Medical Valley EMN—focusing
on clinical research and business matching—and Kalms Consulting, which will
guide park ventures through European regulatory compliance and
commercialization.
Individual
park companies also secured concrete international deals on the show floor:
European
Expansion: CRISPR-based diagnostics developer Orange Biotech signed an MoU with
Hungarian medical device firm CorLab to explore EU distribution and potential
local assembly.
Middle
East Reach: Pushkang Biotechnology partnered with Egypt-based Keen Diagnostic
Partners to deploy and commercialize its automated chemistry analyzers across
Egyptian hospitals and clinics.
Global Product Premieres
Beyond
deal-making, Hong Kong innovators unveiled CE-marked technologies tailored for
global clinical and consumer markets:
AusMed
Global held the European soft launch of KetoMetrics®, the world’s first
portable, real-time breath ketone monitor delivering laboratory-grade accuracy
for metabolic health and weight management.
Dymind
debuted its upgraded DH-8000 hematology analysis workstation, engineered to
streamline high-volume laboratory testing.
Deepening Ecosystem Ties
Throughout
the four-day mission, HKSTP also co-hosted an executive roundtable with global
law firm Clifford Chance and led delegation visits to industry giants including
Siemens Healthineers and TUM Venture Labs. Supported by an ecosystem of over 400
life and health tech companies—several of which recently clinched top honors at
BioJapan 2026 and the Washington Innovation & Entrepreneurship
Competition—HKSTP continues to prove that Hong Kong’s biomedical R&D is
both clinically validated and globally competitive.
Alternative Headlines:
HKSTP
Debuts at MEDICA 2026, Inking Major German Alliances to Fast-Track Asia–Europe
MedTech Trade
From
Lab to Global Market: 22 Hong Kong Innovators Forge New European Partnerships
at MEDICA 2026
.jpg)